1.
|
Zhang S, Mao G, Zhang Y, et al:
Association between human atrial natriuretic peptide Val7Met
polymorphism and baseline blood pressure, plasma trough irbesartan
concentrations, and the antihypertensive efficacy of irbesartan in
rural Chinese patients with essential hypertension. Clin Ther.
27:1774–1784. 2005. View Article : Google Scholar
|
2.
|
Trotta R, Donati MB and Iacoviello L:
Trends in pharmacogenomics of drugs acting on hypertension.
Pharmacol Res. 49:351–356. 2004. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Arnett DK and Claas SA: Pharmacogenetics
of antihypertensive treatment: detailing disciplinary dissonance.
Pharmacogenomics. 10:1295–1307. 2009. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Sherva R, Ford CE, Eckfeldt JH, Davis BR,
Boerwinkle E and Arnett DK: Pharmacogenetic effect of the
stromelysin (MMP3) polymorphism on stroke risk in relation to
antihypertensive treatment: the genetics of hypertension associated
treatment study. Stroke. 42:330–335. 2011. View Article : Google Scholar
|
5.
|
Duarte JD, Lobmeyer MT, Wang Z, et al:
Lack of association between polymorphisms in STK39, a putative
thiazide response gene, and blood pressure response to
hydrochlorothiazide. Pharmacogenet Genomics. 20:516–519. 2010.
View Article : Google Scholar : PubMed/NCBI
|
6.
|
Suonsyrjä T, Donner K, Hannila-Handelberg
T, Fodstad H, Kontula K and Hiltunen TP: Common genetic variation
of beta1- and beta2-adrenergic receptor and response to four
classes of antihypertensive treatment. Pharmacogenet Genomics.
20:342–345. 2010.PubMed/NCBI
|
7.
|
Nichols CG: KATP channels as molecular
sensors of cellular metabolism. Nature. 440:470–476. 2006.
View Article : Google Scholar : PubMed/NCBI
|
8.
|
Wang H, Zhang YL and Chen YP: Targeting
small arteries of hypertensive status with novel ATP-sensitive
potassium channel openers. Curr Vasc Pharmacol. 3:119–124. 2005.
View Article : Google Scholar : PubMed/NCBI
|
9.
|
Wang H, Long CL and Zhang YL: A new
ATP-sensitive potassium channel opener reduces blood pressure and
reverses cardiovascular remodeling in experimental hypertension. J
Pharmacol Exp Ther. 312:1326–1333. 2005. View Article : Google Scholar
|
10.
|
Gao S, Long CL, Wang RH and Wang H:
KATP activation prevents progression of cardiac
hypertrophy to failure induced by pressure overload via protecting
endothelial function. Cardiovasc Res. 83:444–456. 2009.
|
11.
|
Wang H, Tang Y, Wang L, Long CL and Zhang
YL: ATP-sensitive potassium channel openers and
2,3-dimethyl-2-butylamine derivatives. Curr Med Chem. 14:133–155.
2007. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Chen YP, Qiu CR and Wang H: Cardiovascular
pharmacological characterization of novel 2,3-dimethyl-2-butylamine
derivatives in rats. Life Sci. 75:2131–2142. 2004. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Chen YP, Cui WY and Wang H: Selective
actions of iptakalim on the subtypes of KATP channels.
Chin Pharmacol Bull. 22:278–284. 2006.
|
14.
|
Long CL, Qin XC, Pan ZY, et al: Activation
of ATP-sensitive potassium channels protects vascular endothelial
cells from hypertension and renal injury induced by hyperuricemia.
J Hypertens. 26:2326–2338. 2008. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Duan RF, Cui WY, Gao HY, et al:
Correlation between ACE gene I/D polymorphism and clinical efficacy
of iptakalim in Chinese Han hypertensive population. Chin J Clin
Pharmacol Ther. 15:961–966. 2010.
|
16.
|
Evans WE and Relling MV: Pharmacogenomics:
translating functional genomics into rational therapeutics.
Science. 286:487–491. 1999. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Bettinaglio P, Galbusera A, Caprioli J, et
al: Single strand conformation polymorphism (SSCP) as a quick and
reliable method to genotype M235T polymorphism of angiotensinogen
gene. Clin Biochem. 35:363–368. 2002. View Article : Google Scholar : PubMed/NCBI
|
18.
|
Lu Jun, Jiang Shan, Ye Song and Li
Chaopin: Detecting drug resistant genetic mutation among
pneumoconiosis patients complicated with tuberculosis in
Mycobacterium tuberculosis L-forms application of PCR-SSCP
technique in Huainan mining district. J Nanjing Med Univ.
3:180–184. 2007.
|
19.
|
Tomita H, Sasaki S, Osanai T, et al:
Mutational analysis of Kir6.1 in Japanese patients with coronary
spastic angina. Int J Mol Med. 18:589–591. 2006.
|
20.
|
Emanuele E, Falcone C, Carabela M, et al:
Absence of Kir6.1/ KCNJ8 mutations in Italian patients with
abnormal coronary vasomotion. Int J Mol Med. 12:509–512.
2003.PubMed/NCBI
|
21.
|
Haïssaguerre M, Chatel S, Sacher F, et al:
Ventricular fibrillation with prominent early repolarization
associated with a rare variant of KCNJ8/KATP channel. J Cardiovasc
Electrophysiol. 20:93–98. 2009.PubMed/NCBI
|
22.
|
Kane GC, Lam CF, O’Cochlain F, et al: Gene
knockout of the KCNJ8-encoded Kir6.1 K(ATP) channel imparts fatal
susceptibility to endotoxemia. FASEB J. 20:2271–2280. 2006.
View Article : Google Scholar : PubMed/NCBI
|
23.
|
Pan Z, Huang J, Cui W, Long C, Zhang Y and
Wang H: Targeting hypertension with a new adenosine
triphosphate-sensitive potassium channel opener iptakalim. J
Cardiovasc Pharmacol. 56:215–228. 2010. View Article : Google Scholar : PubMed/NCBI
|